# Neoadjuvant Chemotherapy Plus Pyrotinib and Trastuzumab for HER2-positive Breast Cancer (NEOTORCH-BREAST05)

> **NCT06832904** · PHASE2 · RECRUITING · sponsor: **First Affiliated Hospital of Zhejiang University** · enrollment: 33 (estimated)

## Conditions studied

- HER2-positive Breast Cancer
- Neoadjuvant Therapy
- Pyrotinib

## Interventions

- **DRUG:** pyrotinib and trastuzumab in combinition with neoadjuvant chemotherapy

## Key facts

- **NCT ID:** NCT06832904
- **Lead sponsor:** First Affiliated Hospital of Zhejiang University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-12-03
- **Primary completion:** 2028-01
- **Final completion:** 2030-01
- **Target enrollment:** 33 (ESTIMATED)
- **Last updated:** 2025-02-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06832904

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06832904, "Neoadjuvant Chemotherapy Plus Pyrotinib and Trastuzumab for HER2-positive Breast Cancer (NEOTORCH-BREAST05)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06832904. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*